Celltrion reports record Q1 profit up 115.5%, revenue hits 1.14 trillion won

Celltrion has achieved a landmark first quarter, posting its best-ever performance for the period with a significant surge in both revenue and operating profit. The biopharmaceutical giant announced on May 6th that its consolidated operating profit for the first quarter of this year jumped 115.5% compared to the same period last year, reaching 321.9 billion won.

“

Consolidated operating profit for the first quarter increased by 115.5% year-on-year to 321.9 billion won.

This impressive financial growth was mirrored in the company's top line, with revenue climbing 36% year-on-year to 1.145 trillion won. This marks a historic high for Celltrion in a first quarter, demonstrating the company's robust market position and the success of its strategic initiatives. The strong results underscore Celltrion's consistent ability to deliver value and expand its global footprint.

“

Revenue increased by 36% to 1.145 trillion won during the same period, marking the highest first-quarter performance on record.

Celltrion attributes this record-breaking performance primarily to the successful global market expansion of its five high-margin biosimilar products. This strategic focus on biosimilars, which offer more affordable alternatives to biologic drugs, has proven to be a key driver of profitability and growth. The company's continued investment and innovation in this area position it favorably for sustained success in the competitive pharmaceutical landscape.

“

The company explained that the performance was driven by the expanded global sales of five high-margin biosimilar products.